Regenxbio (RGNX) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts RGNX Hot Sheet
Join SI Premium – FREE
Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.01), $0.12 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $21.21 million versus the consensus estimate of $23.47 million.
For earnings history and earnings-related data on Regenxbio (RGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Old Republic International (ORI) to Outperform
- Utah Medical Products (UTMD) Tops Q3 EPS by 87c
- Hyperscale Data reaffirms 2027 revenue guidance of $300M-$350M
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
